login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NEUROPACE INC (NPCE) Stock News
USA
- NASDAQ:NPCE -
US6412881053
-
Common Stock
9.94
USD
+0.08 (+0.81%)
Last: 10/31/2025, 8:03:44 PM
10.13
USD
+0.19 (+1.91%)
After Hours:
10/31/2025, 8:03:44 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NPCE Latest News, Press Relases and Analysis
All
Press Releases
11 days ago - By: NeuroPace, Inc.
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
2 months ago - By: NeuroPace, Inc.
NeuroPace to Participate in Upcoming Healthcare Conferences
3 months ago - By: The Motley Fool
NeuroPace Revenue Jumps 22 Percent in Q2
3 months ago - By: The Motley Fool
NeuroPace (NPCE) Q2 2025 Earnings Call Transcript
3 months ago - By: Zacks Investment Research
- Mentions:
ARAY
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: NeuroPace, Inc.
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
3 months ago - By: Benzinga
- Mentions:
BKV
IMCC
VALN
PRTS
...
Earnings Scheduled For August 12, 2025
3 months ago - By: Zacks Investment Research
- Mentions:
STXS
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
PRCT
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
OFIX
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
3 months ago - By: NeuroPace, Inc.
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
3 months ago - By: NeuroPace, Inc.
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: NeuroPace, Inc.
NeuroPace Announces Strategic CFO Transition
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: The Schall Law Firm
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Yahoo Finance
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: NeuroPace, Inc.
NeuroPace Secures Up to $75 Million in Debt Financing
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Benzinga
- Mentions:
GLD
MRVL
NVDA
REGN
...
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
5 months ago - By: Yahoo Finance
- Mentions:
IVVD
ENPH
HOWL
KROS
...
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
5 months ago - By: Yahoo Finance
- Mentions:
IVVD
HOWL
THC
KROS
...
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5 months ago - By: Yahoo Finance
- Mentions:
RCKT
NVDA
AZO
BLK
...
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Please enable JavaScript to continue using this application.